De novo or acquired resistance to chemotherapeutic drugs continues to be one of the most important obstacles hindering the successful treatment of cancer patients. Consequently, enhancing the efficacy of conventional chemotherapeutic drugs has become an important research goal. Our previous studies using the mouse EMT-6 mammary carcinoma selected for resistance to various alkylating agents in vivo demonstrated that such acquired drug resistance may be manifested in vitro only in cells growing in a three-dimensional configuration but not in conventional monolayer culture. We also found that this phenomenon, which we refer to as "acquired multicellular resistance," is associated with an increase in intercellular adhesion or compaction of the alkylating agent-resistant cell lines grown as aggregates in three-dimensional culture. Purpose: The present study further investigates the impact of three-dimensional architecture on acquired multicellular drug resistance and its influence on cell cycle kinetics, cell cycle arrest, and cell survival. Methods: To test the hypothesis that an increase in three-dimensional compaction is related to the drug resistance properties of the cells, we did the following: 1) selected clones of the EMT-6 cell line that spontaneously formed tightly or loosely adherent aggregates and assessed their respective drug resistance properties in vitro; 2) assayed tumorigenic potential of the tight and loose clones after exposure to defined concentrations of the activated form of cyclophosphamide, 4-hydroperoxycyclophosphamide (4-HC) in vitro; and 3) treated the tight clones with hyaluronidase, an agent capable of disrupting EMT-6 spheroids, and assayed what effect this treatment had on chemosensitivity. We used fluorescence-activated cell sorter analysis to monitor any potential alterations in cell cycle kinetics. Results: The increase in compaction in threedimensional culture was sufficient to confer resistance to 4-HC. This increase in intercellular adhesion was also associated with a lower proliferating fraction of tumor cells and with an almost completely diminished ability of the cells to arrest in the G 2 /M phase of the cell cycle after drug exposure. Furthermore, these changes were detectable only in three-dimensional culture, not in conventional monolayer culture. In conventional monolayer culture, all cell types consistently showed a high level of proliferation and arrested in G 2 /M after exposure to 4-HC. Moreover, hyaluronidase was able to disrupt intercellular adhesion and chemosensitize tumor cells both in vitro and in vivo in an as-
De novo or acquired resistance to chemotherapeutic drugs continues to be one of the most important obstacles hindering the successful treatment of cancer patients. Since current treatment modalities rely heavily on chemotherapeutic drugs and new cytotoxic agents discovered during the last decade are seldom much better than those used historically, enhancing the efficacy of conventional drugs (chemosensitization) has become an important research goal. Hyaluronidase, although relatively nontoxic by itself, has been used as a chemosensitizer in combination with many chemotherapeutic drugs (1 -9) . Its efficacy as a chemosensitizer in treating cancer patients was discovered serendipitously when a patient receiving chemotherapy for myeloma was unintentionally given a paravenous injection and then immediately given hyaluronidase at the same site (7) . (Hyaluronidase was also given, since it is known to speed up the resorption of cytostatic agents and help to prevent unwanted necrosis in normal tissues.) The unexpected improvement in this patient's condition stimulated Baumgartner et al. (7) to assess in more detail the potential of using hyaluronidase as a chemosensitizer. A limited number of experimental and clinical studies (7) (8) (9) have now documented the benefits of combining hyal-uronidase with chemotherapeutic drugs, and an encouraging phase I study (2) has shown that hyaluronidase is well tolerated and causes minimal increases in normal tissue toxicity. It is unclear, however, how hyaluronidase is able to enhance drug-induced cytotoxicity toward tumor cells, although increased drug diffusion in hyaluronic acid (HA)-rich regions of tumors has been proposed (7, 8) .
In order to further rationalize the use of hyaluronidase and to optimize its efficacy or design alternative chemosensitizers, it would be of benefit to understand more fully how hyaluronidase is able to chemosensitize tumor cells to cytotoxic drugs. Many biochemical resistance mechanisms have been described, including, among others, reduced drug accumulation, increased drug efflux, increased metabolic drug detoxification, and increased DNA repair. Almost all acquired drug resistance mechanisms described so far were uncovered by examining drug-resistant variants derived by the continuous or stepwise drug selection of cells growing in monolayer culture. Unfortunately, the impact of such mechanisms on acquired clinical drug resistance in tumors remains unclear, and translational studies (at least in the case of solid tumors) have been mostly disappointing (70) .
By use of drug-resistant cell lines selected for resistance in vivo, instead of in tissue culture, it may be possible to uncover resistance mechanisms that have a greater probability of explaining the basis of clinical drug resistance in solid tumors (11) (12) (13) . In this regard, Teicher et al. (11) generated a series of alkylating agent-resistant variants of the EMT-6 mouse mammary carcinoma by repeatedly exposing syngeneic, tumor-bearing BALB/c mice to various cytotoxic drugs. Although highly resistant in vivo, the drug-selected variants unexpectedly lost their resistant phenotype when cells were grown in conventional monolayer culture (11). Subsequently, our laboratory (14) found that the drug resistance properties of these cells could be "rescued" in vitro if the cells were grown under three-dimensional culture conditions (i.e., as multicellular tumor spheroids). This resistance, which we refer to as "acquired multicellular resistance," was also associated with an increase in intercellular adhesion (or compaction) of the drug-resistant variants compared with the loosely adherent EMT-6 parental cell line (EMT-6/P). In another study (15) , using both the mouse EMT-6/P and human MDA-MB-231 breast cancer cell lines, we have shown that a transient increase in both aggregate compaction and drug resistance can occur rapidly following exposure to 4-hydroperoxycyclophosphamide (4-HC), an activated form of cyclophosphamide.
The purpose of the present study was to determine whether or not this increase in intercellular adhesion observed in three-dimensional culture was sufficient to confer resistance to 4-HC. Because hyaluronidase was able to disrupt this type of compaction in EMT-6 mouse mammary tumor cells, it was used as a tool to address this question. In addition, in a series of experiments, we exposed randomly selected cellular variants displaying different degrees of adhesion in three-dimensional culture to 4-HC and then examined the cells for changes in cell cycle kinetics, cell cycle arrest, and cell survival. We conclude that intercellular adhesion plays a causal role in resistance of solid tumor cells to 4-HC, possibly through alterations in cell cycle kinetics.
Materials and Methods
Animals. All animal experiments were performed on 18-to 23-g female BALB/c mice (The Jackson Laboratory, Bar Harbor, ME) between 6 and 10 weeks of age. Mice were fed Purina autoclavable rodent chow 5010 and housed in sterile microisolator cages. Animal care was in accord with institutional guidelines.
Tumor cell lines and cell culture. The mouse EMT-6 mammary tumor parental cell line (EMT-6/P) and its in vivo derived alkylating agent-resistant variants (previously referred to as EMT-6/LTX and EMT-6/CDDP but hereafter referred to as E/CTX and E/CDDP) (11) were a gift from Dr. Beverly A. Teicher of the Dana-Farber Cancer Institute, Boston, MA. EMT-6 multicellular aggregates were prepared by the liquid overlay technique, as previously described (14) . All EMT-6 cells were cultured in Waymouth's MB 752/1 medium (Life Technologies, Inc. [GIBCO BRL], Gaithersburg, MD), supplemented with 10% fetal calf serum (FCS) at 37 'C in 5% CO 2 and 95% air. Our panel of clones that form tightly or loosely adherent cellular aggregates was obtained by cloning the EMT-6/P cell line by limiting dilution, expanding and then plating the clones into three-dimensional culture, and selecting the most extreme clones that displayed either a tight (compact) or loose morphology. The letter "T" or "L" following the designated name of each clone was used to indicate the "tight" or "loose" morphology of the clone, respectively; the lower-case letter "c" with a number indicates the clone number. Clones retained their respective adhesive phenotypes for at least 2-3 months in culture. For all experiments reported here, frozen stocks less than 1 month old were used.
In vitro colony formation assay. In order to allow maximal and uniform drug exposure, cells growing in monolayer culture were treated with various concentrations (6-100 \iM) of 4-HC for 1 hour, after which cells were rinsed, trypsinized, and replated in three-dimensional culture. In the case of the hyaluronidase experiments, drug-treated cells were simultaneously replated back into monolayers or into spheroid cultures and grown in the presence or absence of hyaluronidase. After 3 days of culture under these conditions, cells were rinsed again, trypsinized, and plated at various dilutions in a colony formation assay (14) . In the time course experiment, cells were exposed to 50 \lM 4-HC in monolayer culture and left for 24, 48, or 72 hours in three-dimensional culture before being plated in the colony formation assay. Surviving fraction (SF) was calculated by the following formula: SF = plating efficiency (PE) of the drugtreated group/PE of the untreated control. Average values ± standard deviations from triplicate wells were used to calculate PE. These experiments were repeated at least three times with similar results.
In vivo tumorigenicity assay. An in vivo tumorigenicity assay was designed to test resistance to 4-HC. Cells from tight or loose clones growing in threedimensional culture for 2 days were exposed to 15 \xM 4-HC; 24 hours later, they were rinsed with phosphate-buffered saline (PBS) and trypsinized, and 5 x ICT cells were injected subcutaneously into syngeneic BALB/c mice. The same experimental procedure was used in the hyaluronidase experiments, except that cells of one of the tight clones, E/Pc5-T, were maintained in three-dimensional culture in complete medium containing 2 mg/mL of hyaluronidase. Tumor volume (V) was calculated by the formula V = d*DP., where d = the smallest tumor diameter (mm) and D = the largest tumor diameter (mm).
Bromodeoxyuridine (BrdU) incorporation assay. Cells growing in either three-dimensional culture for 2 days or in monolayer culture were pulsed with 10 \lM BrdU for 3 hours, after which cells were immediately rinsed with PBS, trypsinized, rinsed again, and fixed with 70% ethanol (4 'Q for at least 1 hour. Cells were rinsed of ethanol with PBS, pelleted, resuspended in 1 mL of cold 0.1 N HCl-0.7% Triton X-100, and left for 10 minutes on ice. After adding 2 mL of PBS, spinning the mixture (5 minutes, 1000 rpm, 4 'C), and decanting the supernatant, we resuspended the cells in 0.5 mL of distilled H 2 O and transferred them into a 0.5-mL Eppendorf tube already containing 16 ^L of 0.1 N HC1. Next, Eppendorf tubes were heated in a polymerase chain reaction machine for 8 minutes at 95 *C and then placed immediately on ice for 10 minutes. After being transferred to a 5-mL tube and rinsed two times with HNFN buffer (i.e., 10 m/W HEPES [pH 7.4]. 150 mM NaCI, 4% FCS, and 0.1% NaNj) and once with HNFN-0.5% Tween 20, pellets were resuspended in 200 nL of a 1/40 dilution of fluorescein isothiocyanate-anti-BrdU antibody (Cedarlane Laboratories Ltd., Homby, ON) and left in the dark on ice for 45 minutes. Stained cells were rinsed twice with HNFN and once with HNFN-Tween 20, pelleted, resuspended in 1 mL of PI solution (i.e., 50 |ig/mL of propidium iodide and 10 Jlg/mL of ribonuclease A in PBS), and left for 1 hour (4 "Q in the dark before they were analyzed on an Epics Elite V flow cytometer (Coulter Electronics, Burlington, ON, Canada).
Disruption of intact spheroids using hyaluronidase. Addition of hyaluronidase to the medium could prevent cell aggregation or disrupt preformed compact spheroids even after 2 or more days of growth in three-dimensional culture. In all experiments reported here, 2 mg/mL of bovine testicular hyaluronidase (Sigma Chemical Co.. Mississauga. ON) was used because it was nontoxic and highly effective.
Assay of adhesion molecule expression. Levels of messenger RNA (mRNA) and protein expression of several adhesion molecules (CD44, E-cadherin, and integrins p", and O^fiJ were analyzed by standard northern blot, western blot, and fluorescence-activated cell sorter (FACS) procedures.
Monitoring cell cycle perturbations after 4-HC exposure. EMT-6 cells growing either in three-dimensional culture or in monolayer culture for 2 days were exposed to 15 UJW 4-HC and then left for 48 hours. In other experiments, cells maintained in the presence or absence of hyaluronidase were exposed to various concentrations of drug and left for 24 hours or followed over time and then collected. To block the cells at the G^M phase of the cell cycle, 1 ug/mL of Nocodazole (Sigma Chemical Co.) in dimethyl sulfoxide (DMSO) or else DMSO alone (0.08% vol/vol) (control) was added to the growth medium at the time cells were plated in three-dimensional culture. For DNA analysis, cells were rinsed with PBS, trypsinized, fixed in 70% ethanol for at least 1 hour, rinsed again with PBS, filtered through 30-um mesh, and then stained with PI solution.
In vivo survival assay. E/Pc5-T cells (5X10 6 ) were injected intraperitoneally into BALB/c mice. On days 1, 3, and 5 after injection, control mice received an intraperitoneal injection of either 20 000 U of bovine testicular hyaluronidase in 0.5 mL of PBS or PBS alone. Drug-treated mice were given the same regimen (i.e., hyaluronidase or PBS) combined with 150 mg/kg of cyclophosphamide (given intraperitoneally in PBS); they received three additional treatments on days 11, 13, and 15 (i.e., drug-treated mice received combined treatments on 6 different days).
Statistical analysis. Differences in survival between the drug-treated groups were analyzed statistically by use of the Mann-Whitney test. All P values were two-sided.
Results

Morphology of Cellular Aggregates of Spontaneously Selected Clones of the EMT-6 Cell Line
In this study, we were interested in determining if the increase in three-dimensional compaction that we have observed in mouse EMT-6 mammary carcinoma cells following drug selection in vivo (14) was in any way related to the drug resistance properties of these cells. We hypothesized that the EMT-6 parental population may be heterogeneous with respect to adhesion and that drug exposure could result in the selection of the more resistant "tight" variants. To test this hypothesis, we generated a series of clones of the EMT-6/P cell line. These clones displayed either a tight (compact) or loose morphology when grown in three-dimensional culture but had never been exposed to drug (Fig. 1) . To derive such variants, approximately 200 EMT-6/P random clones obtained by limiting dilution were expanded and plated in three-dimensional culture by use of the liquid overlay technique to assess their spheroid-forming ability. We observed that approximately 70% of the clones formed loose, irregular aggregates (e.g., E/PclO-L, E/Pcll-L, and E/Pcl4-L) indistinguishable in morphology from the EMT-6/P cell line (Fig. 1, upper panel) , while approximately 25% were more adherent with some variability. Notably, about 5% of the clones looked identical to the alkylating agent-resistant variants described previously, i.e., formed very compact spheroids (e.g., E/Pc5-T, E/Pc7-T, and E/Pcl 1-T; Fig. 1 , lower panel) (14) and were therefore maintained along with the loosest clones for further analysis.
Increase in Colony-Forming Ability of EMT-6 Tight Clones After Exposure to 4-HC
We designed an in vitro colony formation assay to measure the survival capacity (clonogenic ability) of our tight and loose clones. Although previous studies (16, 17) indicated that various alkylating agents have little difficulty in penetrating spheroids, limited drug penetration in compact spheroids has been reported to be a mechanism of resistance for certain other high-molecular-weight chemotherapeutic agents (16) (17) (18) (19) (20) . Therefore, we analyzed whether or not resistance could be detected in our system in the absence of any potential barrier to drug penetration. The assay was designed in such a way that it allowed us to compare the drug resistance properties of tight and loose clones exposed to the same concentration of drug. First, tight and loose clones were exposed to 4-HC for 1 hour in monolayer culture (where all cells would be exposed to drug), after which drug was rinsed away; cells were then harvested and plated onto agarose-coated, 24-well dishes, upon which cells spontaneously formed tight or loose aggregates. After 3 days of growth in three-dimensional culture, tight and loose clones were harvested again and plated in a standard colony formation assay. The results obtained suggested that the tight clones were much more resistant to 4-HC than the loose clones (approximately 10-fold EMT-6/P CLONES OF LOOSE MORPHOLOGY
. Selection of clones of the EMT-6 parental cell line (EMT-6/P) displaying tight or loose morphology in three-dimensional culture. Clones of the EMT-6 cell line, obtained by limiting dilution, were expanded and plated into three-dimensional culture to assess their spheroid-forming ability. The tightest and loosest clones were retained, and 10 000 cells of each of the clones were plated onto 96-well plates precoated with agarose. After 2 days of growth under these conditions, aggregates were photographed under 40x magnification (bars = 0.5 mm).
at 50 \iM 4-HC), even when exposed to the drug under identical conditions (Fig. 2, A) .
Protection of EMT-6 Tight Clones From 4-HC-Induced Toxicity in a Tumorigenicity Assay
To verify our in vitro colony formation data, we designed an in vivo tumorigenicity assay that involved exposing the cells growing in three-dimensional culture to 15 \iM 4-HC and injecting 5 x 10 5 cells subcutaneously 24 hours later into syngeneic BALB/c mice. This assay allowed us to measure the tumorigenic capacity of tumor cell populations after exposure to defined drug concentrations in vitro. As shown in Fig. 2 , B, no obvious differences in the in vivo growth properties of tight or loose clones were observed in the untreated controls. In contrast, in the group treated with 15 (iAf 4-HC, all of the tight clones gave rise to tumors much more rapidly than the loose clones, with very little growth delay over that of untreated controls. Furthermore, tumors formed in all of the mice given an injection of tight clones, whereas only a partial tumor take was observed in those mice receiving loose clones (Fig. 2, B, legend) . The E/CTX cyclophosphamide-resistant cell line that was also included as a positive control displayed an even higher tumorigenic capacity than the tight clones.
Cell Cycle Changes of EMT-6 Clones After Exposure to 4-HC
We hypothesized that an increase in adhesion acquired either spontaneously or after drug exposure, by inhibiting cell proliferation, may render cells more resistant to cytotoxic agents known to be most effective against rapidly dividing cells. To assess this possibility, we analyzed the cell cycle kinetics of our panel of tight and loose clones. As shown in Table 1 , when pulsed with BrdU after 2 days of growth in three-dimensional culture, about twofold to fourfold more cells were labeled in loose clones than in tight clones.
Exposure of tumor cells growing either in monolayer culture or as single-cell suspensions to a number of chemotherapeutic
4-Hydroperoxycyclophosphamide (\xM) Fig. 2 . In vitro survival and in vivo tumorigenicity of EMT-6 tight and loose clones after exposure to 4-hydroperoxycyclophosphamide (4-HC) ex vivo. A) Clones exposed to 4-HC in monolayer for 1 hour were dispersed, replated into three-dimensional culture where they were left for 2 days, and then plated into a colony formation assay. B) Cells (5 x lCr) growing in three-dimensional culture either untreated or exposed to 15 UJW 4-HC for 24 hours were dispersed and then injected subcutaneously into BALB/c mice. All mice receiving an injection of non-drug-treated control cells developed tumors (n = 7). The ending "T* or "L" indicates the clones' tight or loose morphology, respectively. Values shown are the averages ± standard error. Days after Injection agents (including 4-HC) is known to induce a G2/M cell cycle arrest (2122). We were interested in analyzing cell cycle changes following exposure of cells to 4-HC and comparing results obtained from cells grown as monolayers or as three-dimensional tight or loose aggregates. As expected, when exposed to 15 \iM 4-HC in monolayer culture, all of our EMT-6 variants were arrested at the G2/M phase of the cell cycle by 48 hours (data not shown; also compare with Fig. 4, A) . Likewise, a significant G2/M arrest was observed in all of the loose clones 48 hours after exposure to 15 \xM 4-HC in three-dimensional culture (Table 2 ). In contrast, the clones displaying tight morphology appeared to be highly resistant to 4-HC-induced cell cycle perturbations (i.e., the distribution of cells throughout the cell cycle was similar to that of controls). It was notable that the resistant sublines E/CTX and E/CDDP were also highly resistant to cell cycle changes in three-dimensional culture (data not shown). Thus, large differences in cell cycle arrest between tightly and loosely adherent cells after exposure to 4-HC were detectable only when the various tumor cell lines were grown in three-dimensional culture, not in conventional monolayer culture.
Role of Hyaluronidase in Prevention of Compaction, Alteration of Cell Cycle Kinetics, and Sensitization of Tumor Cells to 4-HC
Since an increase in adhesion in three-dimensional culture appears to be sufficient to confer resistance to 4-HC, we were interested in determining if this type of resistance could be reversed by pharmacologically inhibiting intercellular adhesion. We began by investigating the mechanism of adhesion responsible for compaction, but we were unable to identify any obvious differences in the expression of a number of known adhesion molecules between our tight and loose cell lines. Ecadherin, for example, was not detectable by western blot or FACS analysis. Other adhesion molecules, such as the "promiscuous" P) integrin or the epithelial integrin a 6 p 4 , were detected (by northern blot and FACS analysis, respectively) but were expressed at similar levels between the various cell lines. CD44, a major cell adhesion molecule known to bind hyaluronan, was also detected; however, if anything, EMT-6 variants of loose morphology expressed somewhat higher levels of mRNA and protein than those of compact morphology (data not shown). Next, we tried enzymatic means to disrupt adhesion. Although pure preparations of specific enzymes such as collagenase had no effect, bovine testicular hyaluronidase was able to completely disrupt adhesion of compact, preformed spheroids (Fig. 3) . This activity appeared to be specific because pure Streptomyces hyalurolyticus hyaluronidase (ICN Biomedicals, Inc., Costa Mesa, CA) was also able to disrupt compact, preformed spheroids when used in serum-free medium (data not shown). Concomitant with its effects on adhesion, hyaluronidase also increased the proliferation of tight clones in three-dimensional culture to a level similar to that of the loose clones (see Table  1 ). We subsequently evaluated what effect spheroid dissociation by hyaluronidase had on cell cycle kinetics after exposure to 4-HC. As shown in Fig. 4 and Table 2 , spheroids of tight clones dissociated in this manner following exposure to 4-HC showed an S-phase delay followed by an arrest in G2/M. The kinetics with which cells accumulated in G2/M appeared to be dose dependent, and longer S-phase delays were observed at the higher drug concentrations (Fig. 4, A) . In contrast to the hyaluronidasedisrupted cells, we were consistently unable to cause any significant G2/M arrest in either spontaneous or drug-resistant, compact spheroids, even when cells were exposed to up to 50 UJW (Fig. 4, A) or even 100 ]iM (data not shown) 4-HC. We reasoned that, because cells in tight spheroids were cycling more slowly than those in loose, hyaluronidase-treated aggregates (see Table 1 ), it may take longer for the adherent cells in spheroids to arrest in G2/M following drug exposure. However, no significant changes in cell cycle were observed in such compact spheroids, even when left for 96 hours after drug exposure (Fig. 4, B) . Importantly, a proportion of cells from compact spheroids are capable of arresting in G2/M, since addition of the M-phase blocker Nocodazole to the medium resulted in an approximately 15% increase in the fraction of cells arresting in G2/M by 72 hours following drug exposure (Fig. 4, C) . In sharp contrast to the results obtained with compact spheroids, cells from loose aggregates treated with 4-HC and hyaluronidase continued to arrest in G2/M, such that by 96 hours virtually no cells were detectable in any other phase of the cell cycle. By continuously changing the medium, we have followed these cells for more than 2 weeks and have never observed the reappearance of a normal cell cycle profile. We did note, however, that a large proportion of this hyaluronidase-treated population eventually becomes tetraploid (data not shown).
To evaluate the effect of hyaluronidase on adhesion-dependent 4-HC resistance, once again we used our in vitro colony formation assay, which allowed us to measure cell survival in the absence of any potential barrier to drug penetration (Fig. 5, A) .
The assay involved exposure of cells growing in monolayer culture to 4-HC for 1 hour and then harvesting and replating them in either monolayer culture or three-dimensional culture in the presence or absence of hyaluronidase. After 3 days of further growth under these conditions, cells were again harvested and plated in a colony formation assay. The results obtained showed that the most resistant cells were those maintained in threedimensional culture in the absence of hyaluronidase (tight aggregates), followed by those grown in the presence of hyaluronidase (loose aggregates). As reported for many other DNA-damaging agents (23) (24) (25) (26) (27) (28) , cells growing in monolayer culture were much more sensitive to 4-HC than cells growing in three-dimensional culture. The slight increase in drug sensitivity seen in monolayer cultures in the presence of hyaluronidase may be due to the slight increase in cell proliferation observed following exposure to hyaluronidase (see Table 1 ). Because some cell-cell contact is maintained in monolayer culture, it is possible that, even under these conditions, hyaluronidase may increase proliferation by decreasing adhesion.
The results from our colony formation assay revealed that hyaluronidase sensitized cells to 4-HC, especially in threedimensional culture. We were interested in determining how much time was required for this sensitivity to develop. We therefore analyzed the colony-forming ability of cells 24, 48, and 72 hours after exposure to 4-HC in three-dimensional culture (Fig. 5, B) . As expected, cells growing in hyaluronidasecontaining medium were always more sensitive than cells growing in its absence. To our surprise, however, differences in the level of resistance remained relatively constant over the time course, although the number of clonogenic cells increased at a relatively steady rate. This result suggests that the presence of hyaluronidase in the medium during the initial 24 hours after drug exposure is critical for its chemosensitizing activity (compare with results shown in Fig. 6 ). In the presence or absence of hyaluronidase, growth in three-dimensional culture after ex- 
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posure to 4-HC by itself appears to "rescue" cells from otherwise imminent drug-induced loss of clonogenic ability.
As an independent method of measuring the effect of hyaluronidase on 4-HC resistance, we used our assay to measure changes in overall tumorigenicity in vivo after exposure of tumor cells to cytotoxic agents in vitro. In this case, the tight clone E/Pc5-T was grown in three-dimensional culture for 2 days in the presence or absence of hyaluronidase and exposed to various concentrations of 4-HC; 24 hours later, 5 x 10 3 cells were injected subcutaneously into BALB/c mice. As shown in Fig. 5 , C, pre-exposure to hyaluronidase in vitro did not affect the subsequent growth of untreated controls in vivo. When E/Pc5-T cells were treated with 4-HC, however, notable differences in tumor take and latency period were observed, depending on whether or not hyaluronidase was included in the medium. If hyaluronidase was present, for any given drug con- centration, tumor latency was longer and tumor take was less than that observed for cells grown identically except in the absence of hyaluronidase. These changes appeared to be dose dependent such that, at a concentration of 12 \iM 4-HC, E/Pc5-T cells gave rise to tumors only if these cells were grown in the absence of hyaluronidase before injection.
These results stimulated us to determine whether hyaluronidase could also act as a chemosensitizer for cyclophosphamide when both agents are administered simultaneously to mice bearing EMT-6 tumors. For this purpose, we decided to grow EMT-6 tumor cells as ascites, reasoning that such free-floating cellular aggregates may retain properties reminiscent of those observed in three-dimensional suspension culture. To visualize if this hypothesis was true, the tight clone E/Pc5-T growing as an ascites tumor with or without pretreatment with hyaluronidase was removed and analyzed. While many large "spheroid-like" clusters were observed in the untreated group, similar clumps were not found in the hyaluronidase-treated mice (Fig. 6, A) . Next we analyzed the effect of hyaluronidase on survival of drug-treated, tumor-bearing mice. E/Pc5-T ascites tumors were treated repeatedly with hyaluronidase or PBS either alone (controls) or in combination with 150 mg/kg cyclophosphamide, the maximum tolerated dose (drug-treated). Although hyaluronidase by itself did not appear to affect survival time significantly, when it was administered in combination with cyclophosphamide, a significant increase in survival was noted (P<.005) (Fig. 6, B) . Whereas the median survival time was only 28 days in the group treated with cyclophosphamide alone, when cyclophosphamide was administered together with hyaluronidase, half of the mice were still alive at day 47. Thus, hyaluronidase can also inhibit adhesion and act as a chemosensitizer for EMT-6 cells in vivo.
Discussion
Our study shows that an increase in three-dimensional compaction of multicellular tumor spheroids is indeed sufficient to confer resistance to the alkylating agent 4-HC and that hyaluronidase can reverse compaction and sensitize tumor cells to both 4-HC in vitro and to cyclophosphamide in vivo. Thus, adhesive cell interactions may play an important role in both intrinsic and acquired multicellular resistance to alkylating agents. If so, understanding the molecular mechanisms regulating cellular aggregation is of critical importance. The disaggregating effect of hyaluronidase implies the involvement of HA and HA receptors. On the basis of recent experiments, we now believe that there are at least two independent adhesion processes that take place in three-dimensional culture. The initial adhesion event occurs rapidly (within 30 minutes) when cells are placed in three-dimensional culture and is probably shared between the various EMT-6 cell lines. This adhesion appeared weak, inasmuch as cells were easily dispersed from such aggregates by mechanical pipetting (unpublished observation). By staining loosely or tightly adherent variants with nontoxic fluorescent dyes and then mixing the two together and plating them in threedimensional culture, we have observed that, by 6 hours, the tightly adherent cells are able to recognize and homotypically bind to one another. This secondary "homophilic" adhesion mechanism appears to be much stronger than the first, since by 48 hours it is not possible to disperse such clumps mechanically under the same conditions or in the presence of EDTA (unpublished observations). We believe that this latter adhesion mechanism, which is hyaJuronidase sensitive and divalent cation independent, is responsible for the compaction we have observed in the drug-resistant variants and tight clones.
The exact molecular mechanism(s) responsible for compaction of our EMT-6 variants in three-dimensional culture is unknown. The simplest model one can propose is that HA binds to receptors on adjacent cells, thereby forming a molecular bridge which holds compact variants together, and that hyaluronidase, by degrading HA, abolishes this intercellular adhesion. In this regard, Underhill and Toole (29J0) showed that various fibroblast lines transformed with simian virus 40 acquire the ability to bind endogenous HA on adjacent cells using cell surface HA receptors. CD44 has been shown to be the major HA receptor (31) , and it is found on a surprisingly large variety of cell types. The fact that CD44H, the standard form of CD44, appears to be expressed at a slightly higher level in our loosely versus tightly adherent clones may still be consistent with the cross-bridging model if one considers that, in the loose clones, all of the binding sites for HA may be saturated by surfacebound HA, thus preventing cross-bridging from occurring. This hypothesis remains to be tested.
It is interesting that hyaluronidase can increase the growth of our tightly adherent EMT-6 variants, particularly in threedimensional culture. It is possible that hyaluronidase releases growth factors bound to HA (32) or releases small HA fragments that have been shown to stimulate the growth of certain cell types (33) . However, the fact that a similar increase in growth rate can be achieved by selecting for EMT-6 clones that spontaneously form loose aggregates suggests that loss of cellular adhesion per se may constitute a signal regulating cell division. Moreover, conditioned medium from the loose EMT-6 variants did not increase the growth or cause dissaggregation of our tight variants (unpublished observations). It is notable that preferential expression of CD44 and increased HA synthesis have been observed on rapidly proliferating cells (34^5). The HA-binding region of CD44 as well as RHAMM (receptor for HA-mediated motility), another cell surface HA receptor, seems to be essential for the tumorigenic or metastatic properties of various tumor cell lines (36) (37) (38) (39) (40) (41) . Collectively, these studies demonstrate the importance of HA for tumor growth and suggest its possible contribution to adhesion-dependent drug resistance in certain tumors or cell lines.
One of the objectives of the present study was to investigate possible mechanisms by which compaction may contribute to the adhesion-dependent, multicellular drug resistance phenotype. We began by analyzing cell cycle perturbations after drug exposure, since such changes have been assessed only rarely in a solid tumor-like, three-dimensional context (42) . It is surprising that compact spheroids were extremely resistant to 4-HC-induced G2/M arrest, even when they were given supraphysiologic concentrations of drug and left for extended periods of time in three-dimensional culture. It is possible that a proportion of these cells, particularly those near the necrotic core of the spheroid, have become quiescent, thus making these cells relatively unresponsive to 4-HC. However, notable S and G2/M fractions in untreated spheroids suggest that a proportion of spheroid cells, most likely those cells nearest the outer periphery, are cycling. This hypothesis is supported by the fact that cells of compact spheroids display an enhanced G-JM arrest after 4-HC exposure if Nocodazole is added to the medium. Thus, some cells of compact spheroids continue to cycle following drug treatment but are resistant to cell cycle perturbations. Our finding is consistent with the observations made by Sano et al. (42) and Deen et al. (43) , who have shown a similar correlation in spheroids versus monolayers of 9L cells after exposure to the alkylating agent spirohydantoin mustard. The role of adhesion in cell cycle progression and drug sensitivity, however, was not addressed in their studies. Importantly, a number of studies analyzing sequential tumor biopsy specimens before and after chemotherapy (44) (45) (46) have revealed that responsive tumors show a large G2/M arrest that is almost never observed or that is very minimal in unresponsive tumors when it is observed. A similar association between cell cycle arrest and drug sensitivity has also been noted in human tumor xenografts and experimental animal models using cyclosphosphamide and other chemotherapeutic agents (47) (48) (49) (50) .
Since cyclophosphamide is known to be preferentially cytotoxic toward rapidly proliferating cells (51-53), we reasoned that cell adhesion may regulate or affect cell cycle and in turn may indirectly regulate the drug resistance phenotype. At the molecular level, it is unknown why cyclophosphamide is most active against rapidly dividing cells (51-54). The exact mechanism governing adhesion-dependent resistance in our system also remains unclear, although many possibilities exist. For example, since cell-cell and cell-extracellular matrix interactions are known to regulate apoptosis, an increase in intercellular adhesion could potentially inhibit cytotoxic drug-induced programmed cell death (55) (56) (57) (58) . Alternatively, cells in Go/G| may be less susceptible to DNA damage (28, [59] [60] [61] or may be more proficient at repairing their DNA than cells in other phases of the cell cycle (62-65). We believe that the observed decrease in growth with increased adhesion is likely to contribute to the acquired or intrinsic resistance of most solid tumors in patients, especially since labeling indexes in such tumors are low, usually ranging between 1% and 15% (52, 66, 67) . Using fine-needle aspirates to collect breast cancer cells from patients, a number of investigators have monitored cell cycle kinetics by FACS analysis before and after chemotherapy. Such studies have shown retrospectively that patients with rapidly proliferating tumors responded much better to chemotherapy, at least initially, than those with tumors containing a low S-phase fraction (44) (45) (46) (68) (69) (70) (71) (72) (73) . The present study suggests that hyaluronidase may also chemosensitize tumor cells in vivo by stimulating tumor cell growth. Importantly, hyaluronidase treatment by itself did not reduce survival time in vivo. Thus, hyaluronidase may be able to specifically chemosensitize tumor cells without a concomitant increase in normal tissue toxicity.
In summary, this study, which was designed to investigate the nature of multicellular drug resistance, has revealed three novel findings. First, an increase in homotypic cell adhesion, as manifested by an increase in compaction in three-dimensional culture following drug selection in vivo, is sufficient to confer a high level of resistance to the alkylating agent 4-HC. Second, such adhesion is associated with a virtually complete lack of cell cycle perturbations following drug exposure, but only when assayed in three-dimensional culture. Thus, compact spheroids mimic what has previously been noted only in resistant versus sensitive tumors of patients or resistant cell lines derived and analyzed in experimental animals; i.e., cells from resistant tumors maintain a large Go/G, population after drug exposure. Third, hyaluronidase is able to sensitize tumor cells to 4-HC within 24 hours of drug exposure by a mechanism independent of increased drug penetration. This mechanism is likely to be related to the "anti-adhesive" effect of hyaluronidase, which recruits cells into the cycling pool, rendering them more sensitive to 4-HC. Our in vivo results indicate that hyaluronidase is also able to act as a chemosensitizing agent for cyclophosphamide when both agents are administered simultaneously to mice bearing ascites tumors of EMT-6 compact clones where many of the cells grow as aggregated clusters, i.e., as spheroids. We have also begun to test other cell lines and have observed that hyaluronidase is unable to abolish adhesion and sensitize all tumor cell lines to 4-HC. The chemosensitizing activity of hyaluronidase may depend, therefore, on whether or not HA is cross-bridging cells together. If this is true, in these cases perhaps other tumor-specific "anti-adhesives" may be effective in combination with cell cycle-specific drugs (74, 75) . Alternatively, it may be more feasible, at least in the case of solid tumors, to therapeutically target the downstream signal transduction pathways that are regulated by adhesive interactions at the cell surface.
